Drugs in MeSH Category Antipyretics

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	ACETAMINOPHEN	acetaminophen	TABLET, EXTENDED RELEASE;ORAL	207229-001	Nov 9, 2016		OTC	No	No
Bayer	BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN	aspirin	TABLET;ORAL	021317-001	Oct 18, 2001		DISCN	No	No
Gland	ACETAMINOPHEN	acetaminophen	SOLUTION;INTRAVENOUS	219215-002	Apr 2, 2025	AP2	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Antipyretics

Last updated: April 26, 2026

How big is the Antipyretics market, and what drives demand?

MeSH “Antipyretics” maps primarily to fever-reducing, symptom-relief therapies used across inpatient and outpatient care. Demand is driven by three repeatable patterns: (1) acute febrile illness incidence, (2) treatment protocols in pediatrics and primary care, and (3) peri-procedural and hospital use for temperature control.

Demand drivers by care setting

Care setting	Dominant use case	Economic impact	Typical product class exposure
Primary care	Self-limited febrile illness and influenza-like illness	High volume, low margin	Generic acetaminophen; generic NSAID antipyretics
Pediatrics	Fever management with dosing-sensitive regimens	Safety and formulation matter	Acetaminophen and ibuprofen formulations with age-appropriate dosing
Inpatient/ED	Acute fever in infection workups and sepsis pathways	Higher utilization per episode	IV or oral acetaminophen; ibuprofen/other NSAIDs where appropriate
Procedural medicine	Temperature control and analgesic-antipyretic regimens	Protocol-driven	Acetaminophen-centered regimens; NSAIDs adjuncts

Pricing and reimbursement dynamics

• Core market is dominated by generics for acetaminophen and many NSAID antipyretics, which compresses price and limits differentiated pricing power.
• Managed care formularies generally maintain broad coverage for legacy antipyretics due to established safety profiles and low cost.
• The pathway to premium pricing typically requires one of the following: an advantaged formulation (pediatric dosing convenience), a differentiated route (IV), or a narrow indication expansion with superior clinical outcomes in that subgroup.

What is the competitive landscape by mechanism?

Antipyretics sit within a mature therapeutic area with stable, well-understood mechanisms. Market differentiation is less about new targets and more about formulation, route, and pediatric-adherence.

Mechanism map and market position

Mechanism	Representative drug classes	Market role	Differentiation pathway
COX inhibition (prostaglandin reduction)	NSAIDs (for example ibuprofen)	Broad, OTC and prescription	Pediatric formulations, low-dose protocols, palatability
Central prostaglandin pathways	Acetaminophen/paracetamol	Cornerstone antipyretic globally	Improved onset/route (IV), fixed-dose pediatric ease
Cytokine pathway modulators	Fever-targeting immunology exists but is not typical antipyretic usage	Niche within broader inflammatory indications	Development is usually under an immune/inflammation indication, not “antipyretic”

Where do patents still matter in Antipyretics?

Patent value in antipyretics concentrates in:

1. Formulations and routes (for example, IV acetaminophen, extended-release, pediatric liquid stability),
2. Combination products where patents cover dosing regimens or specific fixed combinations,
3. New delivery systems (controlled release, temperature-stable pediatric formats),
4. Method-of-use claims (narrow treatment protocols) where the claim scope survives generic challenges.

Typical “patentable” areas for antipyretics

• Route of administration: IV vs oral has historically supported longer exclusivity for certain products even when the active ingredient is generic.
• Pediatric presentation: dosing devices, flavoring systems with dosing accuracy claims, and age-appropriate strengths can support patent families.
• Combination formulations: fixed combinations with defined ratios can be protected when paired with specific clinical use claims.
• Therapeutic use claims: antipyretics as part of defined infection or peri-procedural protocols can be claimed, though these are often challenged for obviousness and lack of novelty.

What is the patent landscape structure (families, expiry risk, and generic entry pressure)?

Lifecycle pattern

• Active ingredients (acetaminophen, ibuprofen, aspirin where used) have long patent histories and are widely generic.
• Residual patent value persists via late-cycle product patents on route and formulation, plus secondary method-of-use claims.
• Investors typically face a two-speed landscape:
  • Ingredient patents are mostly expired.
  • Product-line exclusivity windows still close unevenly by geography, dosage form, and regulatory approvals.

Expiry-risk implications

• Patent cliffs in antipyretics often do not look like oncology (one blockbuster product with a clear expiry date). Instead, they show portfolio cliffs at the level of dosage form, route, and brand line.
• Generic entry pressure is usually immediate once the last protected product claims clear, especially where:
  • the reference listed drug (RLD) is stable,
  • bioequivalence pathways are straightforward,
  • no remaining exclusivity prevents ANDA filing or launch.

What does the NLM MeSH classification imply for IP scanning and freedom-to-operate?

MeSH classification is an indexing lens, not an IP taxonomy. For antipyretics, it creates a broad net that includes many products whose IP is not protected under “fever” per se. Patent scanning and FTO analysis should therefore treat MeSH as a starting inclusion list, then classify patents by:

• active ingredient (acetaminophen vs NSAIDs),
• dosage form and route (oral, liquid, chewable, IV),
• brand-specific formulation (stability and excipient combinations),
• claim type (composition, formulation, method-of-use),
• geography and regulatory status (patent expiry and exclusivity, not just filing date).

What are the highest-value patent targets within antipyretics?

Priority claim areas for defensibility

Claim category	Why it matters	Typical enforcement posture
Composition and formulation	Excipients, concentration, stability, reconstitution	Often the strongest against generic copies when tied to dosage form
Route-specific claims	IV preparation and related manufacturing constraints	High leverage where generic competitors cannot replicate safely
Method-of-use	Specific dosing intervals, pediatric regimens, or hospital protocols	Often litigated on obviousness and induced infringement
Device-adjacent dosing	Measuring cups, dosing syringes, administration aids	Useful for pediatric adherence but narrower claim scope

What tends to fail

• Broad method-of-use claims that are routine clinical practice.
• Claims that do not tie to a measurable technical effect (for example, improved safety or adherence) in the patent specification.

How do generic penetration and regulatory exclusivity shape near-term market dynamics?

Antipyretics face a predictable pattern:

• OTC and generic penetration reduces price elasticity and compresses revenue.
• Regulatory exclusivity (where available) and specific patent-linked dosage forms extend brand value.
• In hospital systems, formularies often prioritize cost-effective generics after patent expiry, with retention of brands where an IV option or pediatric formulation has protocol value.

What is the practical investment and R&D strategy for Antipyretics?

Given the maturity of the active ingredients, the R&D and investment thesis typically shifts from “new antipyretic drug” to “advantaged product line.”

• Develop or license route- and formulation-differentiated products with clear clinical and workflow advantages.
• Target pediatric-ready presentations and adherence improvements where that can be tied to a defensible formulation or dosing device claim.
• Build patent packages that survive typical generic attack routes by anchoring claims in measurable formulation attributes and robust method-of-use data.

Key Takeaways

• MeSH “Antipyretics” is a mature, high-volume symptom-relief area where patent value concentrates in formulation, route, and narrow method-of-use claims, not new drug targets.
• Competitive dynamics are dominated by generic acetaminophen and NSAIDs, so differentiation must be product-line specific (for example, IV or pediatric formulations).
• Patent scanning should treat MeSH as an inclusion filter, then evaluate dosage form, route, and claim type to map real expiry risk and FTO exposure.
• The most defensible patent targets are composition/formulation and route-specific claims tied to stability, dosing accuracy, and clinical workflow outcomes.

FAQs

1) Which antipyretics dominate the market by volume?

Acetaminophen and common NSAIDs dominate by use frequency and formulary inclusion, with brand revenue largely sustained by specific dosage forms and routes until their product-level exclusivity ends.

2) Why do patents matter more for IV or pediatric products than for the active ingredient itself?

Because the active ingredients are widely generic, exclusivity and defensibility usually hinge on dosage form-specific formulation, manufacturing, and use protocol claims.

3) What claim types are most relevant for freedom-to-operate in antipyretics?

Composition and formulation claims, route-specific claims, and narrow method-of-use claims that map to the exact dosage form and regulatory status of the product being launched.

4) How do generic entry dynamics typically play out after expiry?

Launch is usually rapid once last-protected dosage-form or route claims clear, since bioequivalence and standard formulation pathways reduce barriers to generic substitution.

5) What is the most investable innovation theme in antipyretics?

Product differentiation that creates a defensible IP wall through formulation, route, pediatric usability, or clearly defined clinical protocols rather than a new mechanism.

---

References

1. National Library of Medicine. MeSH (Medical Subject Headings). “Antipyretics.” https://www.ncbi.nlm.nih.gov/mesh/
2. Food and Drug Administration. Drug approval and exclusivity information (regulatory exclusivity overview). https://www.fda.gov/drugs/generic-drugs